Particle.news

Download on the App Store

Supreme Court PIL Seeks CBI Probe as States Widen Bans in India Cough Syrup Deaths

A state lab finding of extreme diethylene glycol in Coldrif batch SR-13 prompted seizures across states, with Tamil Nadu halting production at the manufacturer.

Overview

  • Advocate Vishal Tiwari filed a petition asking the Supreme Court to order a CBI investigation, constitute a judicial or expert commission, and oversee a nationwide review of drug controls and recalls.
  • Madhya Pradesh banned ReLife and Respifresh TR after official tests found diethylene glycol above permitted limits, ordered seizures, and sought action from Gujarat where the syrups were made.
  • Punjab imposed an immediate prohibition on Coldrif sales and use citing the Madhya Pradesh test report, joining other states that have barred the product or issued advisories.
  • A Tamil Nadu inspection of Sresan Pharmaceuticals reported over 350 GMP lapses, unsanitary conditions, missing quality systems, and illegal raw‑material procurement, and authorities stopped production and issued a show‑cause notice.
  • At least 14 children have died in Madhya Pradesh with additional fatalities reported in Rajasthan, while MP police formed an SIT, registered an FIR against the manufacturer, and a paediatrician linked to prescriptions was suspended and arrested.